-
cTAP Study Indicates Duchenne Muscular Dystrophy Clinical Trial Enrollment Criteria Should Expand Beyond Ambulatory Status
Study Co-Funded by CureDuchenne and cTAP Highlights Need for More Specific Enrollment Criteria That Could
-
In ‘Muscle Memoirs,’ I’ll share tales of life with LGMD
Muscular dystrophy entered my life in the fall of 1984. I was 11 years old
-
Finding beauty in how Duchenne has shaped our lives
Duchenne muscular dystrophy (DMD) touches every part of my family’s life. Jason, my husband of
-
REGENXBIO ANNOUNCES NEW POSITIVE DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202
Link to press release We are thrilled to share the latest data from RegenXBio’s microdystrophin
-
Pfizer stops DMD gene therapy development after trial failure
Pfizer has discontinued development of fordadistrogene movaparvovec, its investigational gene therapy for Duchenne muscular dystrophy
-
PepGen Announces Positive Data from Phase 2 Clinical Trial of PGN-EDO51
PepGen Inc. has shared positive clinical data from the first dose cohort (5 mg/kg) of
-
Finding Belonging and Fostering Community
While no one asks to be part of this community, and entering the world of
-
Duvyzat now available to DMD patients 6 and older in US
Duvyzat (givinostat), a newly approved treatment for Duchenne muscular dystrophy (DMD), is now available in
-
Pfizer Discontinues Development of Investigational Mini-Dystrophin Gene Therapy
PPMD is disappointed to learn that Pfizer Inc. has officially discontinued development of the company’s
-
Pfizer Duchenne Program Discontinuation
Pfizer Duchenne Program Discontinuation: Pfizer has officially decided to discontinue their microdystrophin gene therapy program
